DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

Completed

Conditions: Melanoma

Interventions: Other: Blood draw (before surgery)
Other: Blood draw (every 3 months)
Other: Blood draw (at diagnosis)

First Posted Date: 2017-08-30

Last Posted Date: 2023-12-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 37

Registration Number: NCT03267381

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Metastatic Colorectal Cancer
RAS Wild Type Colorectal Cancer
Refractory Colorectal Cancer

Interventions: Drug: Glutaminase Inhibitor CB-839
Biological: Panitumumab
Drug: Irinotecan Hydrochloride (phase I only)
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Device: Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans

First Posted Date: 2017-08-28

Last Posted Date: 2024-08-30

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 29

Registration Number: NCT03263429

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Erdafitinib
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2017-08-03

Last Posted Date: 2024-11-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 35

Registration Number: NCT03238196

Locations: 🇺🇸
Baptist Memorial Hospital MEMPHIS, Memphis, Tennessee, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 3 locations

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Myeloproliferative Neoplasm

Interventions: Drug: Azacitidine Subcutaneous Injection or Intravenous Infusion
Drug: Pevonedistat Infusion
Procedure: Bone Marrow Biopsy & Aspirate

First Posted Date: 2017-08-03

Last Posted Date: 2024-11-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 71

Registration Number: NCT03238248

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States

and more 2 locations

Inherited CAncer REgistry

Recruiting

Conditions: Cancer

First Posted Date: 2017-07-27

Last Posted Date: 2024-03-06

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 10000

Registration Number: NCT03231891

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Invasive Breast Cancer
Triple Negative Breast Cancer
Stage IV Breast Cancer
HER2 Negative

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Other: Laboratory Biomarker
Other: Quality-of-Life Assessment

First Posted Date: 2017-07-02

Last Posted Date: 2024-12-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 106

Registration Number: NCT03206203

Locations: 🇺🇸
Indiana University Health Melvin Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 3 locations

Early Detection of Lung Cancer

Active, not recruiting

Conditions: Lung Cancer

Interventions: Procedure: Biospecimen collection
Procedure: Pulmonary Function Test
Procedure: Computed Tomography (CT)
Other: Laboratory Biomarker

First Posted Date: 2017-06-08

Last Posted Date: 2024-01-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 45

Registration Number: NCT03181256

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Phase 2

Completed

Conditions: Hematopoietic Cell Transplantation

Interventions: Other: Laboratory Biomarker Analysis
Biological: Quadrivalent Inactivated Influenza Vaccine
Biological: Trivalent Influenza Vaccine

First Posted Date: 2017-06-07

Last Posted Date: 2024-12-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 124

Registration Number: NCT03179761

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 1 locations

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Afatinib
Biological: Necitumumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-02-15

Last Posted Date: 2022-04-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 22

Registration Number: NCT03054038

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Phase 2

Withdrawn

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-01-18

Last Posted Date: 2018-04-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT03023904

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy